Join us at the 103th Annual Meeting of American Association for Thoracic Surgery (AATS)

The 103th Annual Meeting of American Association for Thoracic Surgery (AATS) is going to be held at the Los Angeles Convention Center, Los Angeles, CA, USA, from May 6 to 9, 2023: https://events.aats.org/am23.

This time, TCR as well as its sister journals and books published by AME Publishing Company will be on display during this exciting academic event! We would like to seize this great opportunity to meet our authors, editorial board members and readers.

Read More>>

Welcome to join us at the 18^th St. Gallen International Breast Cancer Conference 2023, Vienna, Austria, 15 - 18 March!

The 18^th St. Gallen International Breast Cancer Conference 2023 will be held in Vienna, Austria this year during 15-18 March. More details can be seen: https://www.oncoconferences.ch/events/sg-bcc-2023/.

This time, Translational Cancer Research (TCR) as well as its sister journals and books published by AME Publishing Company will be on display during this exciting academic event! We will also seize this great opportunity to meet our authors, editorial board members and readers.

Read More>>

TCR 2022 Annual Report

Greetings from the Editorial Office of TCR!

We are pleased to share the 2022 Annual Report of Translational Cancer Research. 2022 has seen much progress for TCR. We hope 2023 will bring greater things to TCR. We would like to thank you for your support and assistance in improving the journal over the past year, and we certainly look forward to your innovations and contributions in 2023.

We would especially like to express our sincere gratitude to the editorial board members, guest editors, reviewers, authors, and readers for all your support and contributions to TCR. We wish you a happy, healthy and prosperous 2023!

Read More>>

Efficacy and safety of chimeric antigen receptor (CAR)-T cell therapy in the treatment of relapsed and refractory multiple myeloma: a systematic-review and meta-analysis of clinical trials

Funnel plot of the therapeutic efficacy of CAR-T therapy for RRMM. CAR, chimeric antigen receptor; RRMM, relapsed or refractory multiple myeloma.

Read More>>

Editors’ Choice

A novel signature based on autophagy-related lncRNA for prognostic prediction and candidate drugs for lung adenocarcinoma

Evaluation of prognostic accuracy of the risk model and other clinicopathological characteristics. (A) Univariate and (B) multivariate cox regression analyses of risk score and other clinical parameters (age, gender, AJCC stage, anatomic location, tobacco history, T, N and M). (C) ROC curves of risk score (AUC =0.721) and other clinical features.

Read More>>

A narrative review for the Hippo-YAP pathway in cancer survival and immunity: the Yin-Yang dynamics

The Hippo-YAP pathway in mammals. Various extracellular signals regulate YAP/TAZ phosphorylation and nuclear localization via the recruitment of MST1/2 (large tumor suppressor 1/2)-LATS1/2 (mammalian STE20-like protein kinase 1/2) kinase cascade by KIBRA and neurofibromatosis type 2 (NF2). Other proteins, such as the adaptor proteins Salvador homologue 1 (SAV1), MOB kinase activator 1 (MOB1), the mitogen-activated protein kinase kinase kinase kinase (MAP4K) and TAO kinases (TAOK) take parts in the cascade.

Read More>>

Editors’ Choice

Severe side effects caused by parenteral nutrition therapy with fat emulsion (10%)/amino acids (15)/glucose (20%) injection: 2 case reports

Large mass lesion was represented in the lower lobe of the right lung by MRI (left), and the hepatic infiltration lesion was found (right). MRI, magnetic resonance imaging.

Read More>>

Bone metastasis of esophageal carcinoma diagnosed as a first primary tumor: a population-based study

Kaplan-Meier analysis of overall survival among esophageal carcinoma patients with bone metastasis: (A) stratified by histology, (B) stratified by T stage, (C) stratified by non-bone organ metastasis, (D) stratified by therapy. SCC, squamous cell carcinoma; AC, adenocarcinoma.

Read More>>

Interviews with Outstanding Authors (2022)

In 2022, many authors make outstanding contributions to our journal. Their articles published with us have received very well feedback in the field and stimulate a lot of discussions and new insights among the peers.

Hereby, we would like to highlight some of our outstanding authors who have been making immense efforts in their research fields, with a brief interview of their unique perspectives and insightful views as authors.

Read More>>

Reviewer of the Month (2022)

In 2022, TCR reviewers continue to make outstanding contributions to the peer review process. They demonstrated professional effort and enthusiasm in their reviews and provided comments that genuinely help the authors to enhance their work.

Hereby, we would like to highlight some of our outstanding reviewers, with a brief interview of their thoughts and insights as a reviewer. Allow us to express our heartfelt gratitude for their tremendous effort and valuable contributions to the scientific process.

Read More>>

New Impact Factor for Translational Cancer Research: 0.496

We are pleased to announce that the Translational Cancer Research (TCR) has attained its latest impact factor update for the 2021 citation year: 0.496.

We strive to follow the best practices in publishing. Here, we would like to extend our heartfelt gratitude to all our Editorial Team Members, Guest Editors, authors, and reviewers for their significant contributions.

Read More>>